Stent-based delivery of antisense oligodeoxynucleotides targeted to the PDGF A-chain decreases in-stent restenosis of the coronary artery

• Published in: Journal of cardiovascular pharmacology Vol. 48; no. 4; p. 184
• Main Authors: Li, Yuxin, Fukuda, Noboru, Kunimoto, Satoshi, Yokoyama, Shin-ichiro, Hagikura, Kazuhiro, Kawano, Taro, Takayama, Tadateru, Honye, Junko, Kobayashi, Naohiko, Mugishima, Hideo, Saito, Satoshi, Serie, Kazuo
• Format: Journal Article
• Language: English
• Published: United States 01.10.2006
• Subjects: Animals; Coronary Restenosis - prevention & control; Coronary Vessels - diagnostic imaging; Coronary Vessels - pathology; Male; Oligonucleotides, Antisense - administration & dosage; Platelet-Derived Growth Factor - antagonists & inhibitors; Platelet-Derived Growth Factor - genetics; Stents; Swine; Ultrasonography, Interventional
• ISSN: 0160-2446
• DOI: 10.1097/01.fjc.0000246940.91191.1f

Although the use of drug-eluting stents (DESs) has been shown to limit neointima hyperplasia, currently available DESs may adversely affect reendothelialization, possibly precipitating cardiac events. We evaluated the effect of an antisense oligodeoxynucleotide (ODN) targeted to the platelet-derived growth factor (PDGF) A-chain on in-stent restenosis in pig coronary artery. A bare metal stent coated with phosphorothioate-linked antisense ODN or nonsense ODN, or a bare metal stent without ODN (control), was implanted in the mid segment of the left anterior descending artery (LAD). Twenty-eight days after implantation, angiography and intravascular ultrasound (IVUS) were performed, the LAD was removed, and stenosis was evaluated pathologically. Volumetric stenosis ratios were 64 +/- 11.9, 44 +/- 3.4, and 26 +/- 3.8% in coronary arteries implanted with control, nonsense ODN-coated, and antisense ODN-coated stents, respectively. In angioscopic findings, the lumen surface was smooth in the stented segments in all groups. Struts of antisense ODN-coated stents were observed embedded in the neointima, whereas embedding was not observed in nonsense ODN-coated stents or control stents, indicating a decrease in hyperplasia in response to antisense ODN treatment. Pathologic findings showed 77 +/- 5.8, 68 +/- 12.2, and 38 +/- 5.3% stenosis in coronary arteries implanted with control stents, nonsense ODN-coated stents, and antisense ODN-coated stents, respectively. A continuous lining of endothelial cells was observed along the lumen of coronary arteries implanted with antisense ODN-coated stents. Stent-based delivery of an antisense ODN targeted to the PDGF A-chain effectively inhibits neointima formation after stent implantation in pig coronary artery by suppressing VSMC hyperplasia and preserving endothelialization. Antisense-ODNs may provide a therapy for in-stent restenosis of the coronary artery.